Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jul 30, 2010

Premium

Arrayit announced this week that it has hired Duane Steele to identify potential partnerships for the commercialization of its OvaDx test for ovarian cancer.

Steele was previously vice president of business development at IVAX Diagnostics and COO of Diamedix, IVAX's wholly owned in vitro diagnostics subsidiary.


Gregory Freitag was elected this week to Pressure BioSciences' board of directors, filling a newly created Class III position.

Freitag is CEO, CFO, and a director of LecTec, an intellectual licensing and holding company, as well as CEO of self-insurance service provider EmployRX. Previously he worked in business development at Pfizer Health Solutions and Guidant and co-founded HTS Biosystems, where he was CEO. His term on the board of directors will expire at Pressure Biosciences' 2011 shareholder meeting.


Wolfgang Renz joined PharmaNet Development Group this week as senior vice president of clinical operations. He will be based in the company's Zurich office where he will oversee its European clinical operations as well as its regional monitoring group in North America.

Previously Renz was general manager of JSS Medical Research, president of Samaritan Therapeutics, and adjunct professor of surgery at Montreal's McGill University.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.